Brian Page, MD
Cardiovascular Disease · Buffalo, NYNPI 1700028933
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $666 of the $783 with a category attached, or 85.0%. 11 manufacturers reported payments, led by AstraZeneca at 34.7% of the total. Reporting peaked in 2020 at $287 and has fallen 92.8% since, to $21 in 2024. That places this record below the midpoint for cardiovascular disease clinicians in NY, where the typical reported total is $1,486.
Across 27 payments — averaging $29.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$272
- Amgen$141
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$138
- Abiomed$57
- Novo Nordisk$35
- Astellas Pharma US Inc$29
- plus $111 from 5 others
What the payments were for
- Food & beverage$66685%
- Education$11715%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 4 | $272 |
| Amgen | 4 | $141 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $138 |
| Abiomed | 2 | $57 |
| Novo Nordisk | 2 | $35 |
| Astellas Pharma US Inc | 2 | $29 |
| Boston Scientific | 1 | $28 |
| Edwards Lifesciences | 1 | $26 |
| Pfizer | 1 | $24 |
| Medtronic | 1 | $21 |
| Novartis | 1 | $13 |
How this compares
$783 in reported general payments places this provider in the 35th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 263 | $362,190 |
| EntrestoSacubitril/Valsartan | 66 | $83,392 |
| JardianceEmpagliflozin | 66 | $62,510 |
| Repatha SureclickEvolocumab | 78 | $58,930 |
| FarxigaDapagliflozin Propanediol | 23 | $32,350 |
| XareltoRivaroxaban | 20 | $15,702 |
| BrilintaTicagrelor | 16 | $14,132 |
| Praluent PenAlirocumab | 27 | $13,563 |
| OzempicSemaglutide | 11 | $9,047 |
| LokelmaSodium Zirconium Cyclosilicate | 11 | $8,695 |
| Metoprolol Succinate | 276 | $5,832 |
| Rosuvastatin Calcium | 117 | $2,592 |
| Atorvastatin Calcium | 146 | $2,535 |
| Bisoprolol Fumarate | 39 | $2,406 |
| Ezetimibe | 84 | $2,389 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $24 | $362,190263 claims |
| NovartisEntresto | $13 | $83,39266 claims |
| AstraZenecaFarxiga, Brilinta, Lokelma | $272 | $55,17650 claims |
| Novo NordiskOzempic | $35 | $9,04711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Buffalo
- Saurabh MalhotraBuffalo$438K
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
- Megha PrasadNew York$813K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.